← Lymphatic Malformation Variant Atlas

PIK3CA M1043I

c.3129G>A NM_006218.3 PI3K-AKT transition, gain of function

Cancer hotspot Recurrent missense variant. COSMIC COSV55873376, COSV55878974, COSV55898229
Population · gnomAD Not observed Absent from the population database, consistent with a somatic, non-inherited driver.
ClinVar Pathogenic/Likely pathogenic VCV000179173
Protein region PI3K/PI4K catalytic Residue 1043 of PIK3CA. UniProt P42336
AlphaMissense likely pathogenic Pathogenicity score 0.96. Computational prediction, not clinical evidence.

Position in PIK3CA 14 catalogued

PI3K-ABD (16–105)PI3K-ABDPI3K-RBD (187–289)PI3K-RBDC2 PI3K-type (330–487)C2 PI3K-typePIK helical (517–694)PIK helicalPI3K/PI4K catalytic (765–1051)PI3K/PI4K ca…11068 aaR88QE109delE110delN345KC420RE542KE545AE545GE545KQ546KQ546RM1043IH1047LH1047R

Reported in CCLA

ISSVA subsetAllele fractionSources
CCLA 5.6%

Bars show the reported allele-fraction range on a 0 to 50 percent axis.

Pathway and targeted therapy

Driver of the PI3K-AKT pathway. Repurposed drugs already used in the clinic for this pathway: alpelisib (PI3Kα inhibitor), sirolimus (mTOR inhibitor).

Open and recent trials (3 in vascular / lymphatic anomalies for alpelisib)

Primary sources (1)

  1. Genomic profiling informs diagnoses and treatment in vascular anomalies.
    Li D, Sheppard SE, March ME, Battig MR, Surrey LF, Srinivasan AS, Matsuoka LS, Tian L, Wang F, Seiler C, Dayneka J, Borst AJ, Matos MC, Paulissen SM, Krishnamurthy G, Nriagu B, Sikder T, Casey M, Williams L, Rangu S, O'Connor N, Thomas A, Pinto E, Hou C, Nguyen K, Pellegrino da Silva R, Chehimi SN, Kao C, Biroc L, Britt AD, Queenan M, Reid JR, Napoli JA, Low DM, Vatsky S, Treat J, Smith CL, Cahill AM, Snyder KM, Adams DM, Dori Y, Hakonarson H. · Nat Med · 2023

Mentioned in 153 publications indexed by Europe PMC.

Cross-references